KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Debt to Equity (2016 - 2023)

Pacific Biosciences Of California (PACB) has 12 years of Debt to Equity data on record, last reported at $0.13 in Q3 2023.

  • For Q3 2023, Debt to Equity changed N/A year-over-year to $0.13; the TTM value through Sep 2023 reached $0.13, changed N/A, while the annual FY2022 figure was $0.31, N/A changed from the prior year.
  • Debt to Equity reached $0.13 in Q3 2023 per PACB's latest filing, down from $0.29 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.31 in Q4 2022 and bottomed at $0.13 in Q3 2023.
  • Average Debt to Equity over 3 years is $0.26, with a median of $0.29 recorded in 2019.
  • The widest YoY moves for Debt to Equity: up 123.86% in 2019, down 123.86% in 2019.
  • A 3-year view of Debt to Equity shows it stood at $0.29 in 2019, then increased by 6.26% to $0.31 in 2022, then crashed by 58.8% to $0.13 in 2023.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.13 in Q3 2023, $0.29 in Q2 2023, and $0.27 in Q1 2023.